Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT/mTOR/HIF1α pathway

27 Jul 2024

Abstract excerpt

Renal cell carcinoma (RCC) is considered a "metabolic disease" characterized by elevated glycolysis in patients with advanced RCC. Tyrosine kinase inhibitor (TKI) therapy is currently an important treatment option for advanced RCC, but drug resistance may develop in some patients. Combining TKI with targeted metabolic therapy may provide a more effective approach for patients with advanced RCC. An analysis of 14...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Ferroptosis and cancer prognosis
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39068164
DOI: 10.1038/s41419-024-06913-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT/mTOR/HIF1α pathwayPMID 39068164Read ↗

The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinomaSemantic proximity Read ↗

The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy.Semantic proximity Read ↗

Glycolysis‐Related Genes Serve as Potential Prognostic Biomarkers in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Metabolic landscape of clear cell renal cell carcinoma and search for metabolites predictive of drug responseSemantic proximity Read ↗

Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinomaSemantic proximity Read ↗

Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progressionSemantic proximity Read ↗

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell CarcinomaSemantic proximity Read ↗

A Glycolysis-Based Long Non-coding RNA Signature Accurately Predicts Prognosis in Renal Carcinoma PatientsSemantic proximity Read ↗

Identifying metabolic reprogramming phenotypes with glycolysis-lipid metabolism discoordination and intercellular communication for lung adenocarcinoma metastasis.Semantic proximity Read ↗

Pan-Cancer analysis of clinical significance and associated molecular features of glycolysisSemantic proximity Read ↗

The Heterogeneity Metabolism of Renal Cell Carcinomas.Semantic proximity Read ↗

Identification of a Three-Glycolysis-Related lncRNA Signature Correlated With Prognosis and Metastasis in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.